Peer-influenced content. Sources you trust. No registration required. This is HCN.

Journal of Clinical OncologySystemic Therapy Update on (177)Lutetium-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: ASCO Rapid Recommendation

The Sartor, et al randomized controlled trial (RCT), which demonstrated a significant improvement in radiographic progression-free survival and overall survival (OS) in patients with PSMA-positive mCRPC, served as the foundation for the 177Lutetium-PSMA-617 (177Lu-PSMA-617) March 2022 approval. The availability of this theranostic option served as a compelling argument for revising the 2014 proposal to include a prompt endorsement of 177Lu-PSMA-617. The mCRPC recommendations are now being updated completely.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form